Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 9
Submit an article Journal homepage
3,032
Views
12
CrossRef citations to date
0
Altmetric
Gastroenterology

An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States

Sandra MilevEvidence Synthesis, Modeling & Communication, Evidera, San Francisco, CA, USA;
,
Marco daCosta DiBonaventuraPatient & Health Impact, Pfizer, Inc, New York, NY, USA; Correspondence[email protected]
,
Peter QuonEvidence Synthesis, Modeling & Communication, Evidera, San Francisco, CA, USA;
,
Jo Wern GohEvidence Synthesis, Modeling & Communication, Evidera, San Francisco, CA, USA;
,
Jeffrey BourretMedical Affairs, Pfizer, Inc, Collegeville, PA, USA;
,
Kathleen Peeples-LamirandeMedical Affairs, Pfizer, Inc, Collegeville, PA, USA;
,
Arif SoonasraMedical Affairs, Pfizer, Inc, Collegeville, PA, USA;
,
Joseph C. CappelleriBiostatistics, Pfizer, Inc, Groton, CT, USA
&
Daniel QuirkMedical Affairs, Pfizer, Inc, Collegeville, PA, USA;
show all
Pages 859-868 | Received 01 Feb 2019, Accepted 08 Apr 2019, Published online: 15 May 2019

Related Research Data

An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States
Source: Figshare
An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States
Source: Figshare

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.